New BOBP ETF Targets US Large-Caps Using CORE16's Proprietary Skewness Model
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2025
0mins
Source: Benzinga
New ETF Launch: Exchange Traded Concepts has launched the CORE16 Best of Breed Premier Index ETF (BOBP), which aims to capitalize on market opportunities through a dynamic rebalancing strategy based on equity skewness, allowing for tactical investment decisions.
Investment Strategy: The fund utilizes a proprietary algorithm to select 50 large-cap U.S. securities, focusing on stocks with favorable performance asymmetries, and represents ETC's expansion into niche ETFs in the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to fall
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 19.560
Low
17.00
Averages
18.86
High
23.00
Current: 19.560
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Colgate-Palmolive Forecasts Continued Growth Amid Market Challenges
- Strong Stock Performance: As of July 3, Colgate-Palmolive's stock has risen 20.4% year-to-date, showcasing its robust market competitiveness and attractiveness to investors within the household and personal care products sector.
- Stable Dividend Yield: Colgate-Palmolive has paid uninterrupted dividends since 1895 and has increased its payout for 63 consecutive years, currently offering a dividend yield of 2.24%, appealing to investors seeking stable passive income despite its relatively high stock price.
- Sales Growth Forecast: The company anticipates net sales growth of 2% to 6% and organic sales growth of 1% to 4% for 2026, demonstrating strong market adaptability and brand strength amid declining sales faced by many peers.
- Geographic Diversification Advantage: Colgate-Palmolive's sales outside North America are more than triple those within, particularly achieving double-digit growth in Latin America and EMEA, enhancing its resilience against U.S.-specific inflationary pressures.
See More
Colgate-Palmolive's Resilience Amid Market Challenges
- Sales Growth Outlook: Colgate-Palmolive is guiding for net sales growth of 2% to 6% in 2026, contrasting with peers facing declines, indicating the company's strong growth potential in a competitive market.
- Brand Portfolio Strength: The company boasts a robust brand portfolio, including Colgate and Palmolive, which has enabled it to navigate inflationary pressures and consumer resistance to price increases effectively, securing its leadership in the household and personal care industry.
- Dividend Stability: Colgate-Palmolive has paid uninterrupted dividends since 1895 and has increased its payout for 63 consecutive years, earning it the title of
See More
Market Rotation Creates Buying Opportunities, Says Jim Cramer
- Market Rotation Insight: Jim Cramer highlights that the recent market rotation has created buying opportunities for high-quality stocks, as many quality companies have been pulled lower by institutional selling despite their unchanged fundamentals, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically points to PepsiCo, suggesting that its recent pullback offers a favorable entry point ahead of its July 9 earnings report, while he also sees potential in Starbucks as its CEO works on a successful turnaround.
- Risky Investment Opportunities: For investors willing to take on more risk, Cramer emphasizes Constellation Brands, noting that despite ongoing concerns about spirits, its beer business appears to be stabilizing, making it worth a look.
- Consumer and AI Dynamics: Cramer mentions that TJX Companies will benefit from weakened consumer spending as an off-price retailer capitalizes on excess inventory from traditional retailers, while a rebound in AI stocks has negatively impacted healthcare stocks, including Johnson & Johnson.
See More
Market Rotation Creates Buying Opportunities for Quality Stocks
- Investment Opportunity: CNBC's Jim Cramer highlighted that the latest market rotation presents buying opportunities for high-quality companies that have been unfairly dragged down by institutional selling, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically mentioned Johnson & Johnson, PepsiCo, Starbucks, Constellation Brands, and TJX as stocks that are undervalued amid market fluctuations, making them worthy of investor attention.
- Market Dynamics: Following last week's jobs report indicating a slowdown in hiring, many large money managers repositioned their portfolios, leading to a drop in high-quality stock prices, which Cramer believes creates a favorable buying environment.
- Sector Impact: Cramer emphasized that discount retailers like TJX may benefit from weakened consumer spending, as excess inventory at traditional retailers provides them with more discounted merchandise, enhancing their competitive edge in the market.
See More
Long-Term Investment Strategy in Healthcare Sector
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, a 9.9% increase year-over-year, with adjusted EPS of $2.70 exceeding analyst expectations, and it forecasts annual sales between $99.7 billion and $100.7 billion, indicating robust growth potential in innovative medicine and medtech.
- Diversification Advantage: Abbott Laboratories achieved Q1 sales of $11.2 billion, up 7.8% year-over-year, with strong performance in medical devices and diagnostics offsetting declines in nutrition, and it expects full-year revenue growth of 6.5% to 7.5%, solidifying its position in global healthcare demand.
- Market Dominance: UnitedHealth Group's Q1 revenue reached $111.7 billion, a 2% increase year-over-year, with its Optum division leveraging data analytics and pharmacy care for vertical integration, projecting full-year EPS exceeding $17.35, up at least 31%, reinforcing its leadership in the U.S. private health insurance market.
- Stable Dividend Returns: Johnson & Johnson, Abbott, and UnitedHealth Group are all Dividend Kings, having increased dividends for 64, 54, and 17 consecutive years respectively, showcasing their strong cash flow management and appeal to long-term investors, particularly in times of economic uncertainty, providing low volatility and high margin of safety.
See More
SpaceX Stock Plummets Post-IPO Amid Historical Trends
- Stock Decline: SpaceX's stock has dropped 23% from its post-IPO high of $202, currently trading at $156, indicating market concerns over its high valuation that may lead to decreased investor confidence.
- Historical Trends: Among the 15 largest IPOs since 2006, the average stock price has fallen 50% within the first year, suggesting that SpaceX's shares could decline further to $67.50 in the coming months, reflecting pessimistic market expectations for its future performance.
- Overvaluation: With a market value of $2 trillion and $19.3 billion in revenue over the past four quarters, SpaceX's price-to-sales ratio stands at 104, nearly double that of Palantir, the highest-valued stock in the S&P 500, indicating that such high valuations are unsustainable.
- Investment Strategy Advice: Historical data shows that investors typically underperform in large IPOs, suggesting that investors should wait for a more attractive buying opportunity rather than rushing in at high prices.
See More
Colgate-Palmolive Forecasts Continued Growth Amid Market Challenges
- Strong Stock Performance: As of July 3, Colgate-Palmolive's stock has risen 20.4% year-to-date, showcasing its robust market competitiveness and attractiveness to investors within the household and personal care products sector.
- Stable Dividend Yield: Colgate-Palmolive has paid uninterrupted dividends since 1895 and has increased its payout for 63 consecutive years, currently offering a dividend yield of 2.24%, appealing to investors seeking stable passive income despite its relatively high stock price.
- Sales Growth Forecast: The company anticipates net sales growth of 2% to 6% and organic sales growth of 1% to 4% for 2026, demonstrating strong market adaptability and brand strength amid declining sales faced by many peers.
- Geographic Diversification Advantage: Colgate-Palmolive's sales outside North America are more than triple those within, particularly achieving double-digit growth in Latin America and EMEA, enhancing its resilience against U.S.-specific inflationary pressures.
See More
Colgate-Palmolive's Resilience Amid Market Challenges
- Sales Growth Outlook: Colgate-Palmolive is guiding for net sales growth of 2% to 6% in 2026, contrasting with peers facing declines, indicating the company's strong growth potential in a competitive market.
- Brand Portfolio Strength: The company boasts a robust brand portfolio, including Colgate and Palmolive, which has enabled it to navigate inflationary pressures and consumer resistance to price increases effectively, securing its leadership in the household and personal care industry.
- Dividend Stability: Colgate-Palmolive has paid uninterrupted dividends since 1895 and has increased its payout for 63 consecutive years, earning it the title of
See More
Market Rotation Creates Buying Opportunities, Says Jim Cramer
- Market Rotation Insight: Jim Cramer highlights that the recent market rotation has created buying opportunities for high-quality stocks, as many quality companies have been pulled lower by institutional selling despite their unchanged fundamentals, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically points to PepsiCo, suggesting that its recent pullback offers a favorable entry point ahead of its July 9 earnings report, while he also sees potential in Starbucks as its CEO works on a successful turnaround.
- Risky Investment Opportunities: For investors willing to take on more risk, Cramer emphasizes Constellation Brands, noting that despite ongoing concerns about spirits, its beer business appears to be stabilizing, making it worth a look.
- Consumer and AI Dynamics: Cramer mentions that TJX Companies will benefit from weakened consumer spending as an off-price retailer capitalizes on excess inventory from traditional retailers, while a rebound in AI stocks has negatively impacted healthcare stocks, including Johnson & Johnson.
See More
Market Rotation Creates Buying Opportunities for Quality Stocks
- Investment Opportunity: CNBC's Jim Cramer highlighted that the latest market rotation presents buying opportunities for high-quality companies that have been unfairly dragged down by institutional selling, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically mentioned Johnson & Johnson, PepsiCo, Starbucks, Constellation Brands, and TJX as stocks that are undervalued amid market fluctuations, making them worthy of investor attention.
- Market Dynamics: Following last week's jobs report indicating a slowdown in hiring, many large money managers repositioned their portfolios, leading to a drop in high-quality stock prices, which Cramer believes creates a favorable buying environment.
- Sector Impact: Cramer emphasized that discount retailers like TJX may benefit from weakened consumer spending, as excess inventory at traditional retailers provides them with more discounted merchandise, enhancing their competitive edge in the market.
See More
Long-Term Investment Strategy in Healthcare Sector
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, a 9.9% increase year-over-year, with adjusted EPS of $2.70 exceeding analyst expectations, and it forecasts annual sales between $99.7 billion and $100.7 billion, indicating robust growth potential in innovative medicine and medtech.
- Diversification Advantage: Abbott Laboratories achieved Q1 sales of $11.2 billion, up 7.8% year-over-year, with strong performance in medical devices and diagnostics offsetting declines in nutrition, and it expects full-year revenue growth of 6.5% to 7.5%, solidifying its position in global healthcare demand.
- Market Dominance: UnitedHealth Group's Q1 revenue reached $111.7 billion, a 2% increase year-over-year, with its Optum division leveraging data analytics and pharmacy care for vertical integration, projecting full-year EPS exceeding $17.35, up at least 31%, reinforcing its leadership in the U.S. private health insurance market.
- Stable Dividend Returns: Johnson & Johnson, Abbott, and UnitedHealth Group are all Dividend Kings, having increased dividends for 64, 54, and 17 consecutive years respectively, showcasing their strong cash flow management and appeal to long-term investors, particularly in times of economic uncertainty, providing low volatility and high margin of safety.
See More
SpaceX Stock Plummets Post-IPO Amid Historical Trends
- Stock Decline: SpaceX's stock has dropped 23% from its post-IPO high of $202, currently trading at $156, indicating market concerns over its high valuation that may lead to decreased investor confidence.
- Historical Trends: Among the 15 largest IPOs since 2006, the average stock price has fallen 50% within the first year, suggesting that SpaceX's shares could decline further to $67.50 in the coming months, reflecting pessimistic market expectations for its future performance.
- Overvaluation: With a market value of $2 trillion and $19.3 billion in revenue over the past four quarters, SpaceX's price-to-sales ratio stands at 104, nearly double that of Palantir, the highest-valued stock in the S&P 500, indicating that such high valuations are unsustainable.
- Investment Strategy Advice: Historical data shows that investors typically underperform in large IPOs, suggesting that investors should wait for a more attractive buying opportunity rather than rushing in at high prices.
See More
